Immunogenicity of an inactivated adjuvanted whole‐virion influenza A (H5N1, NIBRG‐14) vaccine administered by intramuscular or subcutaneous injection |
| |
| Authors: | Daisuke Ikeno Kazuhiko Kimachi Yoichiro Kino Seiichi Harada Kayo Yoshida Shinji Tochihara Shigeyuki Itamura Takato Odagiri Masato Tashiro Kenji Okada Chiaki Miyazaki Kohji Ueda |
| |
| Institution: | 1. The Chemo‐Sero‐Therapeutic Research Institute, Kikuchi Research Center, Kawabe Kyokushi, Kikuchi, Kumamoto 869‐1298;2. National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashi‐Murayama, Tokyo 208‐0011;3. Section of Pediatrics, Fukuoka National Hospital, 4‐39‐1 Yakatabaru, Minami‐ku, Fukuoka, 811‐1394;4. Fukuoka‐West Rehabilitation Center, Fukuoka, Fukuoka 819‐0005;5. Faculty of Health and Welfare, Seinan Jo Gakuin University, 1‐3‐5 Ibori Kokurakitaku, Kitakyusyu 803‐0835, Japan |
| |
| Abstract: | The immunogenicity and safety profile of an inactivated whole‐virion influenza A (H5N1, NIBRG‐14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20–40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection. |
| |
| Keywords: | influenza intramuscular injection pandemic subcutaneous injection |
|
|
